For nearly a century, active US federal investment in biomedical research has delivered breakthroughs that cure diseases, improve quality of life, and drive economic growth. Each dollar the National Institutes of Health (NIH) invests generates multiple dollars in downstream research and development, underpinning the creation of medical products that receive regulatory approval. “Federal investment in biomedical research is a key engine of US competitiveness and prosperity,” said Esther Krofah, EVP of Health at the Milken Institute. “Maintaining such a robust investment will keep the United States at the forefront of global biomedical innovation.”

For more than 30 years, the Milken Institute has supported robust federal funding for biomedical research and a strong regulatory science framework in the United States, driven by the recognition and urgency that patients’ lives depend on it. In recent decades, we have witnessed an unprecedented pace of innovation that has transformed how we treat and prevent disease. Proposed federal cuts to biomedical research at NIH and across our broader research enterprise and regulatory agencies risk significantly stalling that progress. 

The Milken Institute remains committed to serving as a thought partner in efforts to better align federal biomedical research investment with results. We stand ready to collaborate with US scientific and regulatory leaders to shape an agile, efficient, and streamlined biomedical innovation ecosystem—one in which tomorrow’s discoveries bring hope to generations to come.